Five Prime Therapeutics Inc (NASDAQ:FPRX) saw a large decrease in short interest during the month of May. As of May 15th, there was short interest totalling 1,320,000 shares, a decrease of 5.0% from the April 30th total of 1,390,000 shares. Based on an average daily trading volume, of 372,200 shares, the short-interest ratio is currently 3.5 days. Currently, 3.7% of the company’s stock are short sold.
A number of research firms have weighed in on FPRX. Wedbush cut shares of Five Prime Therapeutics from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $12.00 to $5.00 in a research report on Tuesday, February 18th. JPMorgan Chase & Co. cut shares of Five Prime Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Friday, February 28th. Finally, Zacks Investment Research raised shares of Five Prime Therapeutics from a “hold” rating to a “buy” rating and set a $3.75 price target on the stock in a research report on Thursday, April 30th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $7.19.
In other news, major shareholder Bvf Partners L. P/Il acquired 293,587 shares of the firm’s stock in a transaction on Thursday, May 14th. The stock was bought at an average cost of $4.10 per share, with a total value of $1,203,706.70. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 6.40% of the company’s stock.
Shares of NASDAQ FPRX opened at $5.43 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 7.82 and a quick ratio of 7.82. The firm’s 50-day moving average price is $3.19 and its two-hundred day moving average price is $3.91. Five Prime Therapeutics has a 52-week low of $1.75 and a 52-week high of $9.13.
Five Prime Therapeutics (NASDAQ:FPRX) last issued its earnings results on Thursday, May 7th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.67) by $0.10. Five Prime Therapeutics had a negative net margin of 679.63% and a negative return on equity of 72.79%. The firm had revenue of $8.41 million for the quarter, compared to analysts’ expectations of $6.60 million. On average, analysts predict that Five Prime Therapeutics will post -2.44 EPS for the current year.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.
Featured Article: What is a CD ladder?
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.